Phase II trial of oral carmofur in advanced pancreatic carcinoma.
Thirty-one patients with advanced carcinoma of the pancreas and with no prior exposure to chemotherapy were treated with HCFU. This drug was administered orally at a dose of 300-500 mg/m2 in 6-week cycles with a 2-week interval between the cycles. One partial response was observed and 7 patients showed stable disease. The median survival of the 31 patients was 8.3 +/- 5.4 months (range 1.3-20.3 months). The toxicity was moderate.
Kajanti
M J
MJ
Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
Pyrhönen
S O
SO
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000970:Antineoplastic Agents; C017367:carmofur; D005472:Fluorouracil